Skip to main content
SpringerLink
Log in

Infection-related costs higher with dasatinib than nilotinib

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2016 US dollars

Reference

  • Seiter K, et al. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States. Advances in Therapy : 28 Aug 2018. Available from: URL: http://doi.org/10.1007/s12325-018-0772-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Infection-related costs higher with dasatinib than nilotinib. Reactions Weekly 1719, 9 (2018). https://doi.org/10.1007/s40278-018-51564-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-51564-6

Search

Navigation